vitro MTX-induced apoptosis of PHA activated PBMC from MTX treated responding patients compared with the nonresponders indicates that this property may not be a good predictive factor for optimising MTX treatment.
Low dose MTX in RA treatment seems to exert antiinflammatory effects by acting at different levels of the pathophysiological cascade. 8 Several studies have recently shown that low dose MTX may well induce antiproliferative effects on the immune cells owing to the inhibition of dihydrofolate reductase and folate dependent transmethylation as an independent mechanism of apoptosis. We did not confirm (unpublished data) that low dose treatment MTX was sufficient to prime PBMC to apoptosis upon subsequent PHA activation ex vivo. It is interesting that in Cutolo's experiments MTX at a concentration of 50 mg/ml did not induce apoptosis and did not affect the proliferation of RA synovial macrophages. 4 It seems that either the apoptosis of cells in the tissue, which is directly involved in the inflammatory process, is more important than that seen in peripheral blood lymphocytes, or that other mechanisms of the MTX action may be responsible for the clinical improvement in patients treated with low doses of MTX.
Platelet and endothelial activation are requisites for the development of antiphospholipid syndrome T he antiphospholipid syndrome (APS) is characterised by venous and arterial thrombosis, recurrent fetal loss, and by the presence of antiphospholipid antibodies (aPL). 1 aPL are also present in 2% of the healthy population, 2 3 and, with the exception of those with high titres of aPL, there is no clear evidence of an increased incidence of thrombosis throughout the follow up. [2] [3] [4] Thus, one of the key questions is: What causes the development of thrombosis in patients with APS? We suggest that in APS, a persistent procoagulant state, 5 6 a continuous endothelial and platelet activation is present, and this may be detected by raised levels of soluble adhesion molecules.
METHODS AND RESULTS
We prospectively studied the following groups of subjects: (a) 20 patients with APS, 7 10 with primary disease and 10 associated with systemic lupus erythematosus; all had presented an arterial or venous thrombotic episode, or both; (b) 20 subjects with aPL but without any clinical finding (aPL WCF); in these subjects aPL were determined by the unexplained presence of an activated partial thromboplastin time inhibitor; (c) 20 healthy controls (HC).
Lupus anticoagulant was analysed by screening tests (dilute Russell viper venom time, dilute one stage prothrombin time, and sensitised partial thromboplastin time) and confirmed by the viper venom time with phospholipid excess and platelet neutralisation tests. 8 Standardised enzyme linked immunosorbent assays (ELISAs) were used to measure serum levels of anticardiolipin antibodies (Orgentec Diagnostika, Mainz, Germany) 9 ; immunoglobulin G anti-b 2glycoprotein I (anti-b 2 GPI) (IMMCO Diagnostic, Buffalo NY, USA) 10 ; and platelet (P-selectin) and endothelial (E-selectin and intercellular cell adhesion molecule-1, ICAM-1) adhesion molecules (R&D, Minneapolis, USA). In patients with APS, soluble adhesion molecules were measured at the time of the second determination of aPL (8 weeks after thrombosis or after parturition).
At least the lupus anticoagulant or increased serum levels of one of the isotypes of anticardiolipin antibodies was detected in all subjects with APS or aPL WCF. Serum concentrations of anti-b 2 GPI above the normal range were detected in all patients with APS and in 30% of the subjects with aPL WCF.
Those subjects with APS and with aPL WCF all showed increased concentrations of E-selectin, in comparison with HC. P-selectin levels were only significantly increased in patients with APS. ICAM-1 concentrations were similar in each of the groups (table 1) . Patients with primary or secondary APS showed similar concentrations of the adhesion molecules. There was no difference between patients with arterial or venous thrombosis or abortions in respect of these measures (data not shown).
All the patients with APS were treated with dicumarin, maintaining an international normalised ratio of more than 3. During a follow up of 18 months, no significant clinical event was noted. Likewise, no significant change was detectable in the percentage of positivity or in the mean titres of aPL or adhesion molecules.
DISCUSSION
These results demonstrate that the presence of aPL, with or without clinical findings, is linked to increased levels of Pselectin, a marker of endothelial activation; however, serum concentration of ICAM-1, a molecule that mediates the firm adhesion of circulating cells, was normal. Owing to the absence of clinical events during the follow up, we cannot rule out the possibility of an increased expression of ICAM-1 in relation to the appearance of new thrombi.
The presence of simultaneously increased levels of Pselectin in patients with APS supports the suggestion of a platelet activation state as the explanation for the clinical findings in this disease. The persistence of raised levels of adhesion molecules rules out an increased expression of these antigens as a consequence of the recent thrombosis or abortions. Results are shown as mean (SD) unless otherwise stated. *p = 0.004 v primary and secondary APS; **p,0.000 v APS (overall); ***p = 0.034 v subjects with aPL but without clinical findings and p = 0.012 v APS (overall). À None of these patients presented activity data of SLE at the time of the study;`cut off value, 10 GPL/ml and 7 MPL/ml; 1cut off value, 20 IU/ml.
